Simulations Plus Shares Outstanding 2010-2023 | SLP
Simulations Plus shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Simulations Plus Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
20 |
| 2022 |
21 |
| 2021 |
21 |
| 2020 |
19 |
| 2019 |
18 |
| 2018 |
18 |
| 2017 |
18 |
| 2016 |
17 |
| 2015 |
17 |
| 2014 |
16 |
| 2013 |
16 |
| 2012 |
16 |
| 2011 |
16 |
| 2010 |
17 |
| 2009 |
17 |
Simulations Plus Quarterly Shares Outstanding
(Millions of Shares) |
| 2023-08-31 |
20 |
| 2023-05-31 |
20 |
| 2023-02-28 |
21 |
| 2022-11-30 |
21 |
| 2022-08-31 |
21 |
| 2022-05-31 |
21 |
| 2022-02-28 |
21 |
| 2021-11-30 |
21 |
| 2021-08-31 |
21 |
| 2021-05-31 |
21 |
| 2021-02-28 |
21 |
| 2020-11-30 |
21 |
| 2020-08-31 |
19 |
| 2020-05-31 |
18 |
| 2020-02-29 |
18 |
| 2019-11-30 |
18 |
| 2019-08-31 |
18 |
| 2019-05-31 |
18 |
| 2019-02-28 |
18 |
| 2018-11-30 |
18 |
| 2018-08-31 |
18 |
| 2018-05-31 |
18 |
| 2018-02-28 |
18 |
| 2017-11-30 |
18 |
| 2017-08-31 |
18 |
| 2017-05-31 |
18 |
| 2017-02-28 |
17 |
| 2016-11-30 |
17 |
| 2016-08-31 |
17 |
| 2016-05-31 |
17 |
| 2016-02-29 |
17 |
| 2015-11-30 |
17 |
| 2015-08-31 |
17 |
| 2015-05-31 |
17 |
| 2015-02-28 |
17 |
| 2014-11-30 |
17 |
| 2014-08-31 |
16 |
| 2014-05-31 |
16 |
| 2014-02-28 |
16 |
| 2013-11-30 |
16 |
| 2013-08-31 |
16 |
| 2013-05-31 |
16 |
| 2013-02-28 |
16 |
| 2012-11-30 |
16 |
| 2012-08-31 |
16 |
| 2012-05-31 |
16 |
| 2012-02-29 |
16 |
| 2011-11-30 |
16 |
| 2011-08-31 |
19 |
| 2011-05-31 |
16 |
| 2011-02-28 |
16 |
| 2010-11-30 |
17 |
| 2010-08-31 |
16 |
| 2010-05-31 |
17 |
| 2010-02-28 |
17 |
| 2009-11-30 |
17 |
| 2009-08-31 |
14 |
| 2009-05-31 |
17 |
| 2009-02-28 |
17 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Computer Software |
$0.785B |
$0.060B |
|
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|
